Research
Hormonal
GLP-1 agonists are approved for weight loss in addition to their original approval for type 2 diabetes.
Healthcare providers should consider GLP-1 agonists for patients needing weight loss support.
StrongSupportsmedium confidence
One of the beneficial effects of this medication class is weight loss, and recently the FDA has approved a select few for this indication of weight loss.
Why this rating
The claim is based on FDA approval, which is a strong form of evidence.
Source
GLP-1 Agonists for Weight Loss and Beyond
Connor Quinter et al. · Transformative Medicine · 2024
DOI 10.54299/tmed/curq6915
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →